Related resources
Full-text held externally
Search for item elsewhere
University researcher(s)
Academic department(s)
Systemic ciclosporin and tacrolimus in dermatology.
Madan V, Griffiths CEM
Dermatol Ther. 2007;20( 4):239-50.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
Abstract
Ciclosporin and tacrolimus are calcineurin inhibiting immunosuppressant agents useful in the treatment of immune-mediated inflammatory dermatoses. Available data and clinical experience demonstrate ciclosporin's efficacy in treating psoriasis, atopic dermatitis, pyoderma gangrenosum, lichen planus, autoimmune bullous disease (in combination with corticosteroids), recalcitrant chronic idiopathic urticaria, and chronic dermatitis of the hands and feet. Although the role of topical tacrolimus in atopic dermatitis is well established, such experience with the oral formulation of tacrolimus has been limited. However, there are several case studies and anecdotal reports of the successful use of oral tacrolimus in various dermatoses. In this article we discuss the utility of systemic ciclosporin and tacrolimus in dermatology.
Keyword(s)
Animals; Humans; Practice Guidelines as Topic; adverse effects: Cyclosporine; adverse effects: Tacrolimus; antagonists & inhibitors: Calcineurin; drug therapy: Skin Diseases; therapeutic use: Immunosuppressive Agents